The global panuveitis treatment market, valued at USD 3.76 billion in 2023, is projected to experience remarkable growth, reaching an estimated USD 8.9 billion by 2033. This expansion corresponds to a robust compound annual growth rate (CAGR) of 9.5% during the forecast period from 2023 to 2033.
There are several treatment options available for Panuveitis, including corticosteroids, immunosuppressants, biologics, and other anti-inflammatory drugs. The choice of treatment depends on the severity and underlying cause of the disease, as well as the patient’s overall health and medical history.
North America is expected to dominate the global Panuveitis treatment market due to the high prevalence of uveitis and related diseases in the region. Europe is expected to be the second-largest market for Panuveitis treatment, owing to the increasing prevalence of autoimmune diseases in the region. Asia-Pacific is also expected to show significant growth, due to the large patient population, rising healthcare expenditure, and increasing awareness about the disease.
Key Takeaways from the Market Study:
- The global panuveitis treatment market is expected to grow with a 9.5% CAGR during 2023 to 2033.
- By distribution channel, hospital pharmacies are expected to hold 49% of the market share in 2023 for Panuveitis treatment market.
- North America is expected to possess 45% market share for Panuveitis treatment market in 2023.
- Europe Panuveitis treatment market size is expected to possess 36% market share in 2023.
“Investment in research and development by key players along with development of innovative therapies is driving the growth of the market,” states an FMI analyst.
Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!
Competitive Landscape:
Key players in the Panuveitis treatment Market are Allergan, Inc., Novartis AG, Bausch Health Inc., AbbVie Inc., Tarsier Pharma, EyeGate Pharmaceuticals, Inc., Alimera Science Inc., Eyepoint Pharmaceutical, Santen Pharmaceutical
- Allergan, Inc. has developed a drug called Ozurdex (dexamethasone intravitreal implant) for the treatment of non-infectious posterior segment uveitis, which includes panuveitis. Ozurdex is a sustained-release implant that delivers a potent corticosteroid (dexamethasone) directly into the eye, where it reduces inflammation and swelling.
- Novartis AG has developed a drug called Ilaris (canakinumab) for the treatment of various inflammatory disorders, including certain forms of uveitis, including panuveitis. Ilaris is a monoclonal antibody that selectively binds to a pro-inflammatory protein called interleukin-1 beta (IL-1β), which is involved in the development of inflammation.
Key Segments Profiled in the Panuveitis Treatment Industry Survey
Drug Class:
- Anti-inflammatory
- Antimicrobial Drugs
- Immunotherapy & Targeted Therapies
Route of Administration:
- Oral
- Topical
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube